European Journal of Molecular & Clinical Medicine

Abstract

In December 2019, an outbreak due to extreme acute Coronavirus 2 (SARS-Cow-2) respiratory syndrome was first identified in Wuhan, China. The 2019 global coronavirus disease (COVID-19) pandemic in 2020 culminated in an extraordinarily strong risk for spreading. No medications in large-scale trials have been validated with substantial effectiveness of clinical care for COVID-19 patients considering the declining pattern of COVID-19. Remdesivir is deemed the most promising antiviral agent; it acts by inhibiting RNA-dependent polymerase RNA function (RdRp). No medications in large-scale trials have been validated with substantial effectiveness of clinical care for COVID-19 patients considering the declining pattern of COVID-19. Remdesivir is deemed the most promising antiviral agent; it acts by inhibiting RNA-dependent polymerase RNA function (RdRp). No medications in large-scale trials have been validated with substantial effectiveness of clinical care for COVID-19 patients considering the declining pattern of COVID-19. Remdesivir is deemed the most promising antiviral agent; it acts by inhibiting RNA-dependent polymerase RNA function (RdRp).